C17orf89 Inhibitors
LY294002 inhibits the PI3K/Akt signaling pathway, which is pivotal for cell survival and metabolism, and can thus affect the proteins that control the expression or function of C17orf89. Compounds such as U0126 and PD98059 are specific MEK inhibitors that can prevent the activation of the MAPK/ERK pathway, a key regulator of cell proliferation and differentiation, which in turn may impact the phosphorylation state and function of proteins that interact with C17orf89. The p38 MAPK pathway, targeted by SB203580, is related to cellular responses to stress and inflammation, and modification of this pathway can have implications for the stability or activity of C17orf89.
MG132 inhibits the proteasome, thereby preventing the degradation of proteins, which could stabilize regulatory proteins that modulate the expression or interaction partners of C17orf89. Wnt-C59 and DAPT target the Wnt and Notch signaling pathways, respectively, both of which are crucial in cell fate determination and may govern the transcriptional regulation of genes including C17orf89. Y-27632, a ROCK inhibitor, can affect cytoskeletal organization and cell motility, which may influence the cellular context and localization of C17orf89. SP600125, a JNK inhibitor, can modify activity within the JNK signaling pathway, which may alter processes in which C17orf89 is involved. Nutlin-3 acts as an MDM2 antagonist that stabilizes p53, a transcription factor that can regulate the expression of various genes, potentially including C17orf89.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTOR signaling pathway, which may regulate the synthesis or degradation of C17orf89. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that can downregulate the PI3K/Akt signaling pathway, which may influence the expression or activity of C17orf89. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can alter stress response pathways, potentially affecting the function or stability of C17orf89. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor that can prevent the degradation of proteins, which may stabilize proteins that regulate C17orf89 or its pathway partners. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
An inhibitor of Wnt production that can disrupt the Wnt signaling pathway, potentially modulating the expression of C17orf89. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A gamma-secretase inhibitor that can impede Notch signaling, which may control transcription factors related to C17orf89 expression. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor that can modify cytoskeleton dynamics and cell motility, possibly influencing the cellular context of C17orf89. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that can affect the JNK signaling pathway, potentially modulating processes that involve C17orf89. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that can block ERK activation, which may affect the signaling pathways regulating C17orf89. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
An MDM2 antagonist that can stabilize p53, potentially influencing the transcriptional regulation of genes including C17orf89. | ||||||